SCHEMBL25073308

SCHEMBL25073308

O=C(O)c1ccc(NS(=O)(=O)c2cnc(-c3ccc(F)cc3)s2)cn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P4HTM Q9NXG6 8/20 0.49
▸ PTPN11 Q06124 1/20 0.45
▸ MEN1 O00255 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ GLA P06280 2/20 0.38
▸ RAB9A P51151 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ RORC P51449 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CSNK2A2 P19784 1/20 0.36
▸ CSNK2A1 P68400 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25072408 0.87 PTPN11 (0.51) P4HTMPTPN11MEN1MAPTKMT2A
SCHEMBL25073028 0.86 PTPN11 (0.44) P4HTMPTPN11MEN1MAPTKMT2A
SCHEMBL25072528 0.85 PTPN11 (0.39) P4HTMPTPN11MEN1MAPTKMT2A
SCHEMBL25073360 0.84 FABP4 (0.45) PTPN11MEN1MAPTKMT2APOLB
SCHEMBL25073358 0.84 PTPN11 (0.43) PTPN11MEN1MAPTKMT2ANPSR1
SCHEMBL25073280 0.83 PTPN11 (0.45) PTPN11MEN1MAPTKMT2APOLB
SCHEMBL25073316 0.83 GAA (0.44) PTPN11MEN1MAPTKMT2APOLB
SCHEMBL25073315 0.83 KMT2A (0.49) PTPN11MEN1MAPTKMT2APOLB
SCHEMBL25073045 0.82 PFKFB3 (0.50) PTPN11MEN1MAPTKMT2APOLB
SCHEMBL30278475 0.81 PTPN11 (0.46) PTPN11MEN1MAPTKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2023-05-11 — — US disclosed
WO-2023023310-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2023-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230143250-A1 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF HSD17B1, HSD17B13, HSD17B3 P4HTM 507/4885PTPN11 3612/4885MEN1 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback